19-nor-hexafluoride analogue of vitamin D3: A novel class of potent inhibitors of proliferation of human breast cell lines

Cancer Research

Volumn 57, Issue 20, 1997, Pages 4545-4550

  Koike, Michiaki ^a   Elstner, Elena ^a   Campbell, Moray J ^a   Asou, Hiroya ^a   Uskokovic, Milan ^b   Tsuruoka, Nobuyoshi ^c   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORIDE; VITAMIN D DERIVATIVE;

ARTICLE; BREAST CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONAL ANERGY; CYTOTOXICITY; DOSE RESPONSE; GROWTH INHIBITION; GROWTH REGULATION; HORMONAL THERAPY; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030767288     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Manni, A. Hormone receptors. In: I. M. Ariel and J. B. Cleary (eds.), Breast Cancer Diagnosis and Treatment, pp. 119-127. New York: McGraw-Hill Book Co., 1987.
2. Berger, U., Wilson, P., McClelland, R. A., Colston, K., Haussler, M. R., Pike, J. M., and Coombes, R. C. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptor in breast cancer. Cancer Res., 47: 6793-6799, 1987.
3. 3. Clin. Endocrinol., 13: 267-272, 1980.
4. 3 receptors in human skin biopsies. J. Clin. Endocrinol. Metab., 51: 1463-1465, 1980.
5. Colston, K. W., Berger, U., and Coombes, R. C. Possible role for vitamin D in controlling breast cancer cells proliferation. Lancet, 28: 188-191, 1989.
6. Eisman, J. K., Martin, T. J., MacIntyre, I., and Moseley, J. M. 1,25-Dihydroxyvitamin-D receptor in breast cancer cells. Lancet, 2: 1335-1336, 1979.
7. Frampton, R. J., Omond, S. A., and Eisman, J. A. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin-D metabolites. Cancer Res., 43: 443-447, 1983.
8. 3. Proc. Natl. Acad. Sci. USA, 76: 4990-4994, 1981.
9. Colston, K. W., Chander, S. K., MacKay, A. G., and Coombes, R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44: 693-702, 1992.
10. Danielpour, D., Kadomatsu, K., Anzano, M. A., Smith, J. M., and Sporn, M. B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res., 54: 3413-3421, 1994.
11. 3, inhibits the growth of human breast cancer in vitro without causing hypercalcemia. Endocrinology, 129: 832-837, 1991.
12. Bower, M., Colston, K. W., Stein, R. C., Hedley, A., Gazet, J-C., Ford, H. T., and Coombes, R. C. Topical calcipotriol treatment in advanced breast cancer. Lancet, 337: 701-702, 1991.
13. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc. Natl. Acad. Sci. USA, 80: 201-204, 1983.
14. 3 prolongs survival time of leukemic mice. Proc. Natl. Sci. USA, 87: 3929-3932, 1990.
15. 3 on the morphology of human breast cancer cell line BT-20. Differentiation, 40: 63-69, 1989.
16. 3: differential effects on leukemic cell growth, differentiation, and intestinal absorption. Cancer Res., 50: 6857-6864, 1990.
17. Mangelsdorf, D. J., Koeffler, H. P., Donaldson, C. A., Pike, J. W., and Haussler, H. R. Induced differentiation in a human promyelocytic leukemia cell line (HL60): receptor-mediated maturation to macrophage-like cells. J. Cell Biol., 98: 391-398, 1984.
18. 3 and its fluorinated analogues. Cancer Res., 44: 5624-5628, 1984.
19. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood, 78: 75-82, 1991.
20. 3 is a potent anti-leukemic agent with low potential to cause hypercalcemia. Leukemia Res., 18: 453-463, 1994.
21. 3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leukemia Res., 19: 65-72, 1994.
22. Elstner, E., Linker-Israeli, M., Said, J., Umei, T., de Vos, S., Shintaku, I. P., Heber, D., Binderup, L., Uskokovic, M., and Koeffler, H. P. 20-epi-Vitamin D analogs: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.
23. Polyak, K., Lee, M-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massagué, T. Cloning of p27 Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
24. 1 cyclin-Cdk protein kinase activity is related to p21. Cell, 78: 67-74, 1994.
25. Spirin, K. S., Simpson, J. F., Takeuchi, S., Kawamata, N., Miller, C. W., and Koeffler, H. P. p27/Kip1 mutation found in cancer. Cancer Res., 56: 2400-2404, 1996.
26. Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massagué, J., Roberts, J. T., and Koff, A. p27 Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
27. Nourse, J., Firpo, E., Flanagan, W. M., Coasts, S., Polyak, K., Lee, M. H., Massagué, J., Crabtree, G. R., and Roberts, J. M. Interleukin-2-mediated elimination of the p27/Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.
28. 1 phase arrest mediated by an inhibitor (p27/Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
29. Ravitz, M., Yan, S., Herr, K. D., and Wenner, C. E. Transforming growth factor beta induced activation of cyclin E-cdk2 kinase and down-regulation of p27/Kip1 in C3H10T1/2 mouse fibroblasts. Cancer Res., 55: 1413-1416, 1995.
30. 3 in HL60 cells. Cancer Res., 56: 264-267, 1996.
31. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood, 84: 1960-1968, 1994.
32. 3 are potent inhibitors of in vitro clonal proliferation of prostate cancer cells PC-3, DU-145, and LNCaP. J. Mol. Endocrinol., 19: 15-27, 1997.
33. Munker, R., Kobayashi, T., Elstner, E., Norman, A. W., Uskokovic, M., Zhang, W., Andreeff, M., and Koeffler, H. P. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood, 88: 2201-2209, 1996.
34. Hirama, T., and Koeffler, H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86: 841-854, 1995.
35. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
36. Kamb, A., Gruis, N. A., Weaver-Fedhaus, J., Liu, Q., Harshman, K., Tavitigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
37. Hannon, G. J., and Beach, D p15 INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
38. Jen, J., Harper, W., Bigner, S. H., Binger, D. D., Papadopoulos, N., Markowitz, S., Wilson, J. K. V., Kinzler, K. W., and Vogelstein, B. Detection of p16 and p15 genes in brain tumors. Cancer Res., 54: 6353-6358, 1994.
39. Guan, K-L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., and Xiong, Y. Growth suppression by p18, a p16 INK4/MTS1- and p14 INK4B/MTS2-ralated CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939-2952, 1994.
40. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90-98, 1994.
41. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinase. Nature (Lond.), 366: 701-704, 1993.
42. El-Deiry, W., Tokino, T., Velculesou, V. E., Levy, D. B., Parsons, R., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 815-825, 1993.
43. 1 cyclin-dependent kinase. Cell, 75: 805-816, 1993.
44. Gu, Y., Turck, C. W., and Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20k regulatory subunit. Nature (Lond.), 366: 707-710, 1993.
45. Jiang, H., and Fisher, P. B. Use of a sensitive and efficient subtraction hybridisation protocol for identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol. Cell. Differ., 1: 285-299, 1993.
46. Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., and Elledge, S. J. p57/Kip2, a structurally distinct member of the p21/C1P1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
47. Lee, M., Reynisdottir, I., and Massagué, J. Cloning of p57/Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639-649, 1995.
48. Chen, J., Jackson, P. K., Kirshner, M. W., and Dutta, A. Separate domains of p21 involved in the inhibition of cdk kinase and PCNA. Nature (Lond.), 374: 386-388, 1995.
49. Luo, Y., Hurwitz, J., and Massagué, J. Cell-cycle inhibition by independent CDK and PCNA-binding domains in p21/Cipl. Nature (Lond.), 375: 159-161, 1995.